scholarly journals Wilderness Medical Society Clinical Practice Guidelines for Diabetes Management

2019 ◽  
Vol 30 (4) ◽  
pp. S121-S140
Author(s):  
Karin D. VanBaak ◽  
Laura M. Nally ◽  
Ryan T. Finigan ◽  
Carrie L. Jurkiewicz ◽  
Andre M. Burnier ◽  
...  
2019 ◽  
Vol 30 (4) ◽  
pp. S33-S46 ◽  
Author(s):  
Grant S. Lipman ◽  
Flavio G. Gaudio ◽  
Kurt P. Eifling ◽  
Mark A. Ellis ◽  
Edward M. Otten ◽  
...  

2019 ◽  
Vol 30 (4) ◽  
pp. S70-S86 ◽  
Author(s):  
Andrew C. Schmidt ◽  
Justin R. Sempsrott ◽  
Seth C. Hawkins ◽  
Ali S. Arastu ◽  
Tracy A. Cushing ◽  
...  

2019 ◽  
Vol 30 (4) ◽  
pp. S3-S18 ◽  
Author(s):  
Andrew M. Luks ◽  
Paul S. Auerbach ◽  
Luanne Freer ◽  
Colin K. Grissom ◽  
Linda E. Keyes ◽  
...  

2019 ◽  
Vol 30 (4) ◽  
pp. S87-S99 ◽  
Author(s):  
Seth C. Hawkins ◽  
Jason Williams ◽  
Brad L. Bennett ◽  
Arthur Islas ◽  
Dietrich Whitfield Kayser ◽  
...  

Author(s):  
V. B. Grinevich ◽  
Yu. A. Kravchuk ◽  
V. I. Ped ◽  
E. I. Sas ◽  
S. P. Salikova ◽  
...  

The presented clinical practice guidelines of the Gastroenterological Scientific Society of Russia (GSSR), diagnostic, and therapeutic approaches for patients with digestive diseases during the COVID-19 pandemic. The guidelines were approved by the XXIII Congress of the GSSR and the 22nd International Slavonic-Baltic Scientifi c Forum “St. Petersburg - Gastro-2020 ON-LINE” (St. Petersburg, June 11, 2020). The presented clinical practice guidelines of the Russian Scientific Medical Society of Internal Medicine (RSMSIM) and the Gastroenterological Scientific Society of Russia (GSSR), diagnostic, and therapeutic approaches for patients with digestive diseases during the COVID-19 pandemic. The recommendations were approved at the XV National Congress of Internal Medicine, XXIII Congress of NOGR on the basis of the 1st edition, adopted at the 22nd International Slavic- Baltic Scientific Forum “St. Petersburg - Gastro-2020 ON-LINE”.


2020 ◽  
Vol 31 (1) ◽  
pp. 50-62 ◽  
Author(s):  
Brad L. Bennett ◽  
Tamara Hew-Butler ◽  
Mitchell H. Rosner ◽  
Thomas Myers ◽  
Grant S. Lipman

2021 ◽  
Vol 22 (4) ◽  
pp. 259-267
Author(s):  
Min Kyong Moon

The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 7th Clinical Practice Guidelines in 2021. Intense multifactorial intervention including adequate control of glycemia, blood pressure, and low density lipoprotein cholesterol level and use of antiplatelet agents has been shown to reduce cardiovascular risk among patients with type 2 diabetes mellitus. In these recent guidelines, sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) with proven benefits were recommended in patients with heart failure and/or atherosclerotic cardiovascular disease (ASCVD) as mono- or combination therapy. SGLT2 inhibitors such as dapagliflozin, empagliflozin, and ertugliflozin were recommended preferentially in patients with heart failure. In those with ASCVD, treatment including SGLT2 inhibitors such as empagliflozin and dapagliflozin or GLP-1 RAs such as dulaglutide, liraglutide, and semaglutide as a combination therapy was recommended.


Sign in / Sign up

Export Citation Format

Share Document